Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
about
Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endotheliumComplement receptor is an inhibitor of the complement cascadeBivalent and co-operative binding of complement factor H to heparan sulfate and heparinAnalysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complementInteractions between human complement components factor H, factor I and C3bStructure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complementFactor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient miceStealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersStructural Basis for Complement Evasion by Lyme Disease Pathogen Borrelia burgdorferiStructural basis for sialic acid-mediated self-recognition by complement factor HCryptic sialic acid binding lectins on human blood leukocytes can be unmasked by sialidase treatment or cellular activationHuman and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activitiesInitiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteinsRegulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membraneAnalysis of the interactions between properdin, the third component of complement (C3), and its physiological activation productsInhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranesMechanism of action of factor D of the alternative complement pathwayInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyThe binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.Identification of complement regulatory domains in vaccinia virus complement control protein.Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome.Self-nonself discrimination by the complement system.Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat modelTnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity.Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59).The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.Complement control protein factor H: the good, the bad, and the inadequate.Multifarious roles of sialic acids in immunity.Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complementAbnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes.Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement.A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosusMicrobes bind complement inhibitor factor H via a common site
P2860
Q22010210-35D0ABCE-5D24-4E21-9412-5A7CB51F94DCQ24302183-D66AC8EA-CFF8-44D9-A7A8-00A23997858BQ24311571-ABEB1AD3-404B-48F7-BEF6-C924CEDEEF8CQ24529520-838E3260-BC82-4BA4-9C18-6E2F424310DEQ24530290-7B9DB50D-1606-4CAA-82D6-D1A2B0EB48B3Q24543850-6C66BFAA-2A07-47F6-850C-B666596B32B0Q24619612-525DBB5F-AD79-44A9-B857-27FD004DEC31Q24651118-CB318323-8C0D-4F01-971B-3C42C8378856Q27496024-4373E533-9DDD-4E32-832E-6A840AFAD5ECQ27678051-8DA5D7B4-2BEF-4BCA-9F42-81EFACCE2F4BQ27696183-591CC3FE-56F7-4AC8-8017-A515768904DFQ28146065-D27666CC-4400-4CDF-8106-A28DD82FA726Q28570196-87EF0A73-02A6-4428-A148-CDFB91A82752Q28610965-590FB2E9-D4E0-4889-A3BF-546157185CF4Q28610966-21395EF7-E7F2-40D0-9890-C1D4F8BFC6E2Q28610971-AB09682F-8A91-4CCC-BD2D-09D9D5FEF7DEQ28610983-12392840-7CF4-466A-B975-C04BAB1D68A8Q28611019-5CCEA564-2918-4280-B5FC-021BE19323CEQ28972389-281C4EDC-8120-47E9-A110-74D75A28EDBEQ30377280-6D46537D-FFFE-4E6A-9B64-CAD3D75BF388Q30447940-E525553D-30B8-4233-9FE0-99819B133F39Q33378236-B75FF5E8-C825-4B4C-9CC6-14DAE43CC1FFQ33384039-2518CB83-1AC5-4E6F-AA47-D09B45CCB50DQ33412152-DA8C74CD-9E1B-4E75-8AC2-F0FC27478DC8Q33433754-E6BFA07E-AF3C-474A-90E5-E392D9E4390AQ33558301-8987B003-26C0-449F-8791-4FB4EC09602FQ33596128-E245EC15-087B-4E95-869E-3E0376D10D87Q33602953-0EDF6CBC-774A-4B71-93CF-A3473B6B305FQ33606633-8A43AFB0-140F-4E69-95AF-FA55105124BFQ33703237-08E19A07-3998-4E97-B951-DC9E368E8ED8Q33752377-D27B47DA-616D-45E8-AF4B-469CFC43073BQ33753497-3152D16B-1A2F-4E4C-9317-04606C6999D6Q33769638-258C5F9E-D60C-4250-8F2C-3CB473AD738CQ34067107-74D9EAE3-BC16-4DE9-9EA0-F8AA41E97E11Q34270155-CEB21374-FC00-4B4D-9E3C-6B7289A3C36BQ34537546-E144211A-303C-4320-8529-E8C7E9E58961Q34608150-CA9DFFC6-2B84-4974-800F-52F5B6FED2B9Q34624357-80A66A5D-F764-4413-AFF0-5E01ACEC4A8EQ34629373-2D7847A1-8C64-402A-9997-FDFC610EE926Q34699715-7007A8C9-042C-4AD2-BCC0-64EC419D47B2
P2860
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1978
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Complement C3 convertase: cell ...... n neuraminidase-treated cells.
@en
Complement C3 convertase: cell ...... n neuraminidase-treated cells.
@nl
type
label
Complement C3 convertase: cell ...... n neuraminidase-treated cells.
@en
Complement C3 convertase: cell ...... n neuraminidase-treated cells.
@nl
prefLabel
Complement C3 convertase: cell ...... n neuraminidase-treated cells.
@en
Complement C3 convertase: cell ...... n neuraminidase-treated cells.
@nl
P2860
P356
P1476
Complement C3 convertase: cell ...... n neuraminidase-treated cells.
@en
P2093
Müller-Eberhard HJ
Pangburn MK
P2860
P304
P356
10.1073/PNAS.75.5.2416
P407
P577
1978-05-01T00:00:00Z